J&J's Invokana closes in on badly needed kidney disease nod with FDA 'priority' boost

23rd May 2019 Uncategorised 0

When it comes to Invokana sales, Johnson & Johnson needs a way to stop the bleeding. And it just got one step closer to a new indication in chronic kidney disease—a distinction its rival SGLT2 drugs don’t have.

More: J&J's Invokana closes in on badly needed kidney disease nod with FDA 'priority' boost
Source: fierce